Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478174 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
A Phase 3 study, sponsored by Haisco-USA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT05478174 is a Phase 3 study that has completed, run by Haisco-USA Pharmaceuticals. The registered enrollment target is 400 participants.
The verdict
NCT05478174, a Phase 3 study, has completed, sponsored by Haisco-USA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.
Interventions
- DRUG Propofol
- DRUG HSK3486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-07-26 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478174
The ClinicalTrials.gov registry entry for NCT05478174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haisco-USA Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propofol is the first listed.
NCT05478174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05478174 about?
NCT05478174 is a clinical study titled "Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia". To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if nee...
What is the current status of trial NCT05478174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2022-07-26. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05478174?
The interventions under investigation include: Propofol (DRUG), HSK3486 (DRUG).
Who is sponsoring clinical trial NCT05478174?
This trial is sponsored by Haisco-USA Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.